Quarterly ResultJul 27, 2026, 04:38 PM
GeoVax Labs Q2 Net Loss $4.43M; Cash $3.14M; Going Concern Warning
AI Summary
GeoVax Labs reported a net loss of $4.43 million for Q2 2026, an improvement from $5.37 million in Q2 2025, but revenue from government contracts ceased. The company's cash and cash equivalents stood at $3.14 million as of June 30, 2026. GeoVax plans to initiate a Phase 3 clinical trial for its GEO-MVA mpox/smallpox vaccine candidate in late 2026 and a Phase 2 trial for Gedeptin® in 2027, while discontinuing its COVID-19 vaccine program. The company also noted that existing cash resources are sufficient only into September 2026, raising substantial doubt about its ability to continue as a going concern without additional funding.
Key Highlights
- Net loss for Q2 2026 was $4.43 million, an improvement from $5.37 million in Q2 2025.
- No revenue from government contracts in Q2 2026, down from $852,282 in Q2 2025.
- Cash and cash equivalents totaled $3.14 million as of June 30, 2026.
- Existing cash resources are sufficient only into September 2026.
- GEO-MVA Phase 3 clinical trial expected to initiate in late 2026.
- Gedeptin® Phase 2 clinical trial planned for initiation in 2027.
- Discontinued GEO-CM04S1 COVID-19 vaccine candidate development.
- Net cash provided by financing activities was $7.25 million for H1 2026.
Price Impact
More from GOVX